title: Human beta-defensin-2 production in keratinocytes is regulated by interleukin-1, bacteria, and the state of differentiation.
abstract: Intact human epidermis resists invasion by pathogenic microbes but the biochemical basis of its resistance is not well understood. Recently, an antimicrobial peptide, human beta-defensin-2, was discovered in inflamed epidermis. We used a recombinant baculovirus/insect cell system to produce human beta-defensin-2 and confirmed that at micromolar concentrations it has a broad spectrum of antimicrobial activity, with the striking exception of Staphylococcus aureus. Immunostaining with a polyclonal antibody to human beta-defensin-2 showed that the expression of human beta-defensin-2 peptide by human keratinocytes required differentiation of the cells (either by increased calcium concentration or by growth and maturation in epidermal organotypic culture) as well as a cytokine or bacterial stimulus. Interleukin-1alpha, interleukin-1beta, or live Pseudomonas aeruginosa proved to be the most effective stimuli whereas other bacteria and cytokines had little or no ability to induce human beta-defensin-2 synthesis. In interleukin-1alpha-stimulated epidermal cultures, human beta-defensin-2 first appeared in the cytoplasm in differentiated suprabasal layers of skin, next in a more peripheral web-like distribution in the upper layers of the epidermis, and then over a few days migrated to the stratum corneum. By semiquantitative Western blot analysis of epidermal lysates, the average concentration of human beta-defensin-2 in stimulated organotypic epidermal culture reached 15--70 microg per gram of tissue, i.e., 3.5-16 microM, well within the range required for antimicrobial activity. Because of the restricted pattern of human beta-defensin-2 distribution in the epidermis, its local concentration must be much higher. Defensins and other antimicrobial peptides of inflamed epidermis are likely to play an important antimicrobial role in host defense against cutaneous pathogens.
authors.affiliation: Department of Medicine, UCLA School of Medicine, Los Angeles, California 90095-1690, USA. tganz@mednet.ucla.edu
authors.forename: Alice Y
authors.initials: AY
authors.lastname: Liu
authors.forename: Delphine
authors.initials: D
authors.lastname: Destoumieux
authors.forename: Annie V
authors.initials: AV
authors.lastname: Wong
authors.forename: Christina H
authors.initials: CH
authors.lastname: Park
authors.forename: Erika V
authors.initials: EV
authors.lastname: Valore
authors.forename: Lide
authors.initials: L
authors.lastname: Liu
authors.forename: Tomas
authors.initials: T
authors.lastname: Ganz
mesh_terms: D000900:Anti-Bacterial Agents / Q000378:metabolism; D018407:Bacterial Physiological Phenomena; D002454:Cell Differentiation / Q000502:physiology; D002478:Cells, Cultured; D006801:Humans; D007375:Interleukin-1 / Q000502:physiology*; D015603:Keratinocytes / Q000166:cytology / Q000378:metabolism* / Q000382:microbiology*; D009924:Organ Culture Techniques; D011994:Recombinant Proteins / Q000378:metabolism; D014018:Tissue Distribution; D023083:beta-Defensins / Q000096:biosynthesis* / Q000378:metabolism
chemical_list: D000900:Anti-Bacterial Agents; C106641:DEFB4A protein, human; D007375:Interleukin-1; D011994:Recombinant Proteins; D023083:beta-Defensins